Identifying reduced blood capillaries in the retina may be a new, noninvasive way to diagnosis early cognitive impairment – an early warning sign of dementia. The findings which are used in new technology are important because of Alzheimer's cannot be cured, if spotted early treatments can slow down its progression. It's known those with Alzheimer's have decreased retinal blood flow and vessel density. But until now it has not been known in these changes are present in individuals with early Alzheimer's or forgetful mild cognitive impairment who have a higher risk of progressing to dementia.
Scientists at Northwestern University Feinberg School of Medicine changes in the human eye non-invasively, with an infrared camera and without the need for dyes or expensive MRI scanners.
The back of the eye is optically accessible to a new type of technology ( changes in great detail and with unparalleled resolution, making the eye an ideal mirror for what is going on in the brain.
Professor of ophthalmology Dr Amani Fawzi said: or biomarker to identify individuals at high risk of progressing to Alzheimer's
"These individuals can then be followed more closely and could be prime candi dates for new therapies aimed at slowing down the progression of the disease or preventing the onset of the dementia associated with Alzheimer's. "Future studies are planned to test the simple new technology at multiple clinics to validate the marker as well as find the best algorithm and combination of tests that will detect high-risk subjects
The study by the Northwestern Mesulam Center for Cognitive Neurology and Alzheimer's Disease involved 32 patients.
They had cognitive testing consistent with the forgetful type of cognitive impairment, and age-, gender- and race- matched them to subjects who tested as cognitively normal for their age.
The data were analyzed to identify whether the vascular capillaries in the back of the eye were different between the two groups of individuals.
Now the team hopes to correlate these findings with other more standard but also more invasive type Alzheimer's biomarkers as well as explore the longitudinal changes in the eye parameters in these subjects. Prof Fawzi added: "Ideally, the retinal findings would correlate well with other brain biomarkers.
" Long-term studies are also important The Alzheimer's Society said there are around 850,000 people in the UK with dementia and it will affect one million by 2025 when we live longer. Alzheimer's disease is the most common type of dementia and the risk increases with age, affecting an estimated one in 1
But around one in every 20 cases of Alzheimer's disease affects people aged 40 to 65. This is called early-or young-onset Alzheimer's disease.
The study was published in the journal PLOS ONE.
While there is no cure for dementia, stud ies have shown ways the condition can be kept at bay – for example, eating this food every day.